



February 17, 2020

Nuclear Materials Licensing Branch
U.S. Nuclear Regulatory Commission, Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

Licensee: Insight Health Corp. C/O CDI
RAML #: **22-29403-01** Amendment 6
Subject: **Amendment Request (Add Authorized Users)**

Dear Sir or Madam:

This is an amendment request to our Radioactive Materials License (RAML) referenced above to add Authorized Users (AU).

- **Please add the following AU's for material and use as found in 10 CFR 35.200:**

Michael J. Maroney, MD

Gary Loh, MD

Carter A. Kenamond, MD

Mark L. Benson, MD

Vincent James Caruso, MD

These physicians are currently listed on Reynolds Memorial Hospital's RAML (**NRC 47-0819-01**). A copy of Reynold's RAML is provided in Attachment 1.

No other changes are needed at this time. All future correspondence may be sent directly to me, and I will distribute the information to the appropriate individuals. Should you require any additional information, please do not hesitate to contact me at (724) 943-6417 or TSikorski@insighthealth.com.

Sincerely,

A handwritten signature in black ink, appearing to read "Anthony Sikorski".

Anthony Sikorski
Area Manager
Insight Health Corp., C/O CDI

CC: Emily Chasteen, M.S., DABR, Corporate Radiation Safety Officer

Enclosures: **Attachment 1:** Reynolds Memorial Hospital's RAML (NRC 47-0819-01)

RECEIVED FEB 19 2020

Attachment 1:

NRC FORM 374		U.S. NUCLEAR REGULATORY COMMISSION		PAGE 1 OF 3 PAGES Amendment No. 48	
MATERIALS LICENSE					
<small>Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.</small>					
Licensee 1. Reynolds Memorial Hospital, Inc. 2. 800 Wheeling Avenue Glen Dale, WV 260381697		In accordance with letter dated May 29, 2019. 3. License number: 47-08019-01 is amended in its entirety to read as follows:		4. Expiration Date: February 29, 2024 5. Docket No.: 030-03384 Reference No.:	
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200	7. Chemical and/or physical form A. Any B. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200.		
CONDITIONS					
10. Licensed material may be used or stored at the licensee's facilities located at 800 Wheeling Avenue, Glen Dale, West Virginia.					
11. The Radiation Safety Officer (RSO) for this license is Michael J. Maroney, M.D.					

Attachment 1:

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 OF 3 PAGES																				
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-08019-01	Docket or Reference Number 030-03384																					
	Amendment No. 48																						
<p>12. Licensed material shall only be used by, or under the supervision of:</p> <p>A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.</p> <p>B. The following individuals are authorized users for the material and medical uses as indicated:</p> <table><thead><tr><th><u>Authorized Users</u></th><th><u>Material and Use</u></th></tr></thead><tbody><tr><td>Eric Roger Balzano, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Mark L. Benson, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Vincent James Caruso, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>John L. DeFilippo, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Eric William Irwin, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Carter A. Kenamond, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Gary Loh, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Michael J. Maroney, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr><tr><td>Michael L. Slaysman, M.D.</td><td>10 CFR 35.100, 10 CFR 35.200</td></tr></tbody></table>				<u>Authorized Users</u>	<u>Material and Use</u>	Eric Roger Balzano, M.D.	10 CFR 35.100, 10 CFR 35.200	Mark L. Benson, M.D.	10 CFR 35.100, 10 CFR 35.200	Vincent James Caruso, M.D.	10 CFR 35.100, 10 CFR 35.200	John L. DeFilippo, M.D.	10 CFR 35.100, 10 CFR 35.200	Eric William Irwin, M.D.	10 CFR 35.100, 10 CFR 35.200	Carter A. Kenamond, M.D.	10 CFR 35.100, 10 CFR 35.200	Gary Loh, M.D.	10 CFR 35.100, 10 CFR 35.200	Michael J. Maroney, M.D.	10 CFR 35.100, 10 CFR 35.200	Michael L. Slaysman, M.D.	10 CFR 35.100, 10 CFR 35.200
<u>Authorized Users</u>	<u>Material and Use</u>																						
Eric Roger Balzano, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Mark L. Benson, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Vincent James Caruso, M.D.	10 CFR 35.100, 10 CFR 35.200																						
John L. DeFilippo, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Eric William Irwin, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Carter A. Kenamond, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Gary Loh, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Michael J. Maroney, M.D.	10 CFR 35.100, 10 CFR 35.200																						
Michael L. Slaysman, M.D.	10 CFR 35.100, 10 CFR 35.200																						
<p>13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.</p>																							

Attachment 1:

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMMISSION		PAGE 3 OF 3 PAGES	
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 47-08019-01	Docket or Reference Number 030-03384			
	Amendment No. 48				
<p>14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.</p> <p>A. Application dated September 12, 2013, except therapy use [ML13274A191] B. Letter dated September 23, 2016 [ML16274A414] C. Email dated March 15, 2017 [ML17082A524]</p> <p style="text-align: center;">FOR THE U.S. NUCLEAR REGULATORY COMMISSION</p> <p>Date: <u>August 7, 2019</u></p> <p>By: <u>Robert H. Gallagher</u> Robert Gallagher Region 1</p>					

ORIGIN ID:BFDA (724) 935-5557
 JUDY DEZI
 CDI
 6400 BROOKTREE COURT
 SUITE 350
 WEXFORD, PA 15090
 UNITED STATES US

SHIP DATE: 18FEB20
 ACTWGT: 1.00 LB
 CAD: 107026809/INET4220

BILL SENDER


TO **NUCLEAR MATERIALS LICENSING BRANCH**
US NUCLEAR REG COMMISSION REG III
2443 WARRENVILLE ROAD
SUITE 201
LISLE IL 60532

55BL2049FE4A

(999) 999-9999
 INV
 PO.

REF: NRC AMENDMENT REQUEST

DEPT:




TRK# 7777 9361 5598
 0201

WED - 19 FEB 3:00P
 STANDARD OVERNIGHT

NA ENLA

60532
 IL-US ORD



After printing this label:

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our ServiceGuide. Written claims must be filed within strict time limits, see current FedEx Service Guide.

RECEIVED FEB 19 2020